SCHEMBL3638176

SCHEMBL3638176

Clc1cccc(NCc2c[nH]nc2-c2cccs2)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 5/20 0.41
LMNA P02545 5/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HTT P42858 1/20 0.41
HPGD P15428 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
GAA P10253 1/20 0.36
HIF1A Q16665 1/20 0.36
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
THRB P10828 1/20 0.35
MAPK14 Q16539 1/20 0.35
NR1H4 Q96RI1 2/20 0.34
PGK1 P00558 1/20 0.34
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635672 0.90 MAPT (0.39) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3638754 0.82 KMT2A (0.41) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3640108 0.82 LMNA (0.42) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3633663 0.81 GAA (0.44) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3636396 0.81 L3MBTL1 (0.43) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3638003 0.81 ADRA2C (0.46) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3637346 0.80 KMT2A (0.42) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3638148 0.79 KDM4E (0.47) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL3635764 0.79 MAPT (0.44) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3634725 0.79 SMN1; SMN2 (0.46) MAPTALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 MAPT 572/4885ALDH1A1 3335/4885LMNA 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.